Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?

Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D.

Arch Pathol Lab Med. 2008 Jan;132(1):23-8. doi: 10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2.

PMID:
18181669
2.

The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.

Hyun TS, Barnes M, Tabatabai ZL.

Acta Cytol. 2012;56(5):527-32. doi: 10.1159/000339586. Epub 2012 Sep 27.

PMID:
23075894
3.

Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H.

Cancer. 2008 Feb 25;114(1):49-56.

4.

Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.

Chhieng DC, Yee H, Schaefer D, Cangiarella JF, Jagirdar J, Chiriboga LA, Jagirdar J, Chiriboga LA, Cohen JM.

Cancer. 2000 Jun 25;90(3):194-200.

PMID:
10896333
5.
6.

The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.

Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF.

Diagn Cytopathol. 2006 Dec;34(12):801-6.

PMID:
17115439
8.

The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.

Shield PW, Koivurinne K.

Cytopathology. 2008 Aug;19(4):218-23. Epub 2007 Oct 4.

PMID:
17916095
9.
10.

Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma.

Pritchard SA, Howat AJ, Edwards JM.

Histopathology. 2003 Aug;43(2):197-9. No abstract available.

PMID:
12877739
11.

Calretinin immunostaining in benign and malignant pleural effusions.

Simsir A, Fetsch P, Abati A.

Diagn Cytopathol. 2001 Feb;24(2):149-52. No abstract available.

PMID:
11169899
12.

Immunocytochemical detection of XIAP in body cavity effusions and washes.

Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE.

Mod Pathol. 2005 Dec;18(12):1618-22.

14.

Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.

Üçer Ö, Dağli AF, Kiliçarslan A, Artaş G.

Turk Patoloji Derg. 2013;29(2):94-100. doi: 10.5146/tjpath.2013.01158.

16.

[Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer].

Sánchez Merino JM, Quintana González JI, Toribio Sánchez CM, Gómez Cisneros SC, Parra Muntaner L, García Alonso J.

Actas Urol Esp. 2002 Jul-Aug;26(7):513-4. Spanish.

PMID:
12224436
17.
18.

Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.

Mocanu L, Cîmpean AM, Raica M.

Rom J Morphol Embryol. 2006;47(4):351-5.

19.

IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.

Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T.

Hum Pathol. 2010 May;41(5):745-50. doi: 10.1016/j.humpath.2009.04.030. Epub 2010 Jan 13.

PMID:
20060157
Items per page

Supplemental Content

Write to the Help Desk